Linvoseltamab
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
What's the purpose of the trial?
The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
Accepting patients
Participating Centers
There are 12 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Bortezomib Bortezomib is a kind of medication called a proteasome inhibitor that interferes with the growth and spread of cancer cells in the body. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma.
- Carfilzomib Carfilzomib is a kind of medication called a proteasome inhibitor that interferes with the growth and spread of cancer cells in the body. Carfilzomib is used in the treatment of multiple myeloma.
- Cemiplimab (REGN2810) is a monoclonal antibody that attaches to the PD-1 protein on the body's immune cells. Cemiplimab may work by stopping cancer cells from being able to inhibit the body's immune system.
- Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
- Fianlimab is a monoclonal antibody that targets the LAG-3 receptor on the body's own T cells. Fianlimab may work by helping to stop cancer cells from shutting down some of our immune system defenses.
- Isatuximab is a type of drug called a monoclonal antibody. Isatuximab targets a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
- Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
- Linvoseltamab is a bispecific antibody being tested for use in multiple myeloma that targets BCMA on cancer cells and CD3 on T-cells .
- Nirogacestat is a selective, reversible, non-competitive gamma-secretase inhibitor drug that is expected to increase the anti-tumor effectiveness of drugs like elranatamab
- Pomalidomide is a kind of medication called an immunomodulatory agent that promotes an immune response to help slow tumor growth. Pomalidomide is used in the treatment of several different indications.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.